Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cue Health Inc. (HLTHQ) is a medical device company that developed a point-of-care molecular diagnostic platform, primarily known for its COVID-19 rapid test. The company filed for Chapter 11 bankruptcy in March 2024 as COVID testing demand collapsed, resulting in an 87% revenue decline. The 'Q' suffix indicates bankruptcy status, with the stock trading as a distressed equity with near-zero market capitalization.
Cue operated a razor-and-blade model selling proprietary handheld molecular diagnostic readers paired with single-use test cartridges. Revenue was generated through direct sales to consumers, healthcare facilities, and government contracts (notably DOD contracts worth $481M in 2021-2022). The business model collapsed as pandemic-era demand evaporated, government contracts ended, and the company failed to diversify beyond COVID testing. Negative gross margins indicate the company is selling products below manufacturing cost, reflecting inventory liquidation and fixed overhead absorption issues.
Bankruptcy proceedings and potential liquidation outcomes (asset sales, creditor recovery rates)
Delisting proceedings and OTC market trading dynamics
Residual government contract revenue recognition or clawbacks
Intellectual property asset valuations in bankruptcy proceedings
Potential acquisition interest in Cue's molecular diagnostic platform technology
Complete equity wipeout in bankruptcy proceedings as creditors are paid before shareholders
Permanent loss of going-concern value as the company lacks viable business model post-pandemic
Regulatory compliance costs for maintaining FDA clearances exceed any potential revenue from residual operations
Technological obsolescence as competitors advanced molecular diagnostics during Cue's financial distress
Abbott, Roche, and Cepheid dominate point-of-care molecular diagnostics with diversified test menus and established distribution
Rapid antigen tests from Quidel, BD, and others captured consumer market at lower price points
Loss of key personnel and institutional knowledge during bankruptcy undermines any technology transfer value
Negative equity position with -90% ROE indicates complete capital impairment
Operating cash flow of -$100M annually with minimal revenue creates unsustainable liquidity drain
Current ratio of 2.54 is misleading as assets include obsolete COVID test inventory with minimal liquidation value
Bankruptcy court may authorize asset sales below book value, further eroding any theoretical equity value
minimal - The company's fate is determined by bankruptcy proceedings rather than economic conditions. Historical business was counter-cyclical (pandemic-driven demand), but current distressed status makes traditional economic sensitivity irrelevant. Any residual operations are not materially affected by GDP growth or consumer spending patterns.
minimal - With near-zero market cap and bankruptcy status, interest rate changes have negligible impact on equity value. The company's debt restructuring in bankruptcy is governed by court proceedings rather than market rates. Higher rates may marginally affect the present value of potential creditor recoveries but do not meaningfully impact equity holders who are likely to be wiped out.
terminal - The company is in Chapter 11 bankruptcy with $0.19 debt-to-equity ratio suggesting some secured debt. Credit conditions are irrelevant as the company cannot access capital markets. Equity holders are subordinated to all creditors and face near-certain total loss. The bankruptcy process will determine asset liquidation values and creditor recovery rates.
distressed debt specialists and bankruptcy arbitrageurs - equity holders are typically retail investors facing total loss or sophisticated distressed investors seeking lottery-ticket outcomes from unexpected asset recoveries. This is not a traditional investment but rather a speculation on bankruptcy proceedings. The stock attracts no institutional equity investors given the near-certain wipeout scenario.
extreme - Penny stock trading with zero fundamental value creates massive percentage swings on negligible volume. Beta is meaningless as the stock is disconnected from market fundamentals. Daily moves of 20-50% are common based purely on bankruptcy news flow or technical trading patterns. Liquidity is minimal with wide bid-ask spreads.